Top

Open Access 11-03-2025 | Progestin | Review

The efficacy of progestins in managing pain associated with endometriosis, fibroids and pre-menstrual syndrome: a systematic review

Authors: Connor Luke Allen, Saikat Banerjee, Mahantesh Karoshi, Peter Humaidan, Farshad Tahmasebi

Published in: Archives of Gynecology and Obstetrics

Abstract

Purpose

Alongside being contraceptives, progestins have been investigated as potential anti-inflammatory and analgesic therapies for use in painful gynaecological conditions. This review aims to synthesise evidence pertaining to the efficacy of progestins as analgesics for use in endometriosis, fibroids and pre-menstrual syndrome (PMS).

Methods

We conducted a systematic review of the extant literature investigating the analgesic efficacy of progestins compared to any comparator interventions for individuals with the three specified gynaecological conditions. The search was carried out across the PubMed and CENTRAL databases on 7 April 2024 for randomised control trials (RCTs) published in the peer-reviewed literature from 2000 onwards. Data pertaining to analgesic efficacy, assessed by changes in pain indices/scores before and after treatment, were synthesised narratively. Data pertaining to adverse effect frequency and changes in bone mineral density (BMD) were also synthesised narratively. Risk of bias was assessed using the Cochrane risk of bias 2 tool.

Results

The primary search identified 1220 potentially eligible RCTs of which 21 were ultimately included; 19 RCTs related to endometriosis, two related to fibroids and zero related to PMS. Quality assessment identified nine studies to be at a low risk of bias, nine studies with some concerns surrounding bias and three studies to be at a high risk of bias. The included studies represented a total of 2745 participants of whom 1317 were treated with a progestin and 1428 received a comparator intervention. In 18 of the 19 studies concerning endometriosis, progestins produced a statistically significant reduction in pain, further, in five instances progestins were more efficacious in reducing pain than comparator interventions. In both studies on fibroids, progestins produced significant reductions in pain, however, statistically significant differences compared to comparator interventions were not demonstrated. The most frequently cited adverse effect of progestins was spotting/irregular bleeding whilst those receiving comparator interventions most often reported hot flushes; cited in 12 and seven studies respectively. Five studies assessed the impact of progestins and comparators on BMD. Three studies found progestins significantly reduced BMD, however, in these instances reductions were significantly lower than those produced by comparator interventions and in two studies were not statistically significant after 12 months of follow-up.

Conclusion

Our review demonstrates the potential scope for the use of progestins as analgesics in the management of pain associated with endometriosis. Further research will need to be conducted to identify their efficacy in the management of pain associated with fibroids and PMS.

Available only for authorised users

Edwards M, Can AS Progestin [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK563211/ (2023). Accessed 10 December 2024.

McCartney CR, Marshall JC (2019) Chapter 1 - Neuroendocrinology of Reproduction. In: Strauss JF, Barbieri RL (eds) Yen and Jaffe’s Reproductive Endocrinology, 8th edn. Elsevier, Philadelphia, pp 1–24

Han L, Creinin MD, Hemon A, Glasier A, Chen MJ, Edelman A (2022) Mechanism of action of a 0.075 mg norgestrel progestogen-only pill 2. Effect on cervical mucus and theoretical risk of conception. Contraception 112:43–7. https://doi.org/10.1016/j.contraception.2022.03.016CrossRefPubMed

Bastianelli C, Farris M, Bruni V, Rosato E, Brosens I, Benagiano G (2020) Effects of progestin-only contraceptives on the endometrium. Expert Rev Clin Pharmacol 13(10):1103–1123CrossRefPubMed

Sales K, Jabbour H (2003) Cyclooxygenase enzymes and prostaglandins in reproductive tract physiology and pathology. Prostaglandins Other Lipid Mediat 71(3–4):97–117CrossRefPubMed

Grandi G, Mueller M, Bersinger N, Papadia A, Nirgianakis K, Cagnacci A et al (2016) Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells. Am J Obstet Gynecol 76(4):292–298. https://doi.org/10.1111/aji.12552CrossRef

van der Burg B, van der Saag PT (1996) Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. Mol Hum Reprod 2(6):433–438PubMed

Kupec T, Wagels L, Caspers R, Meyer-Wilmes P, Najjari L, Stickeler E et al (2024) Predictors of anxiety in endometriosis patients. Arch Gynecol Obstet. https://doi.org/10.1007/s00404-024-07878-4CrossRefPubMedPubMedCentral

Vercellini P, Viganò P, Somigliana E, Fedele L (2014) Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 10(5):261–275CrossRefPubMed

10.

World Health Organization. Endometriosis [Internet]. https://www.who.int/news-room/fact-sheets/detail/endometriosis (2023). Accessed 20 March 2024.

11.

Horne AW, Missmer SA (2022) Pathophysiology, diagnosis, and management of endometriosis. BMJ 2022(379):e070750CrossRef

12.

Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S (2016) Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril 106(7):1552–1571. https://doi.org/10.1016/j.fertnstert.2016.10.022CrossRefPubMed

13.

de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T et al (2014) Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014(3):CD010813. https://doi.org/10.1002/14651858.CD010813.pub2CrossRefPubMedPubMedCentral

14.

Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM (2016) Progestin-only contraception and thromboembolism: a systematic review. Contraception 94(6):678–700. https://doi.org/10.1016/j.contraception.2016.04.014CrossRefPubMedPubMedCentral

15.

Brown J, Crawford TJ, Datta S, Prentice A (2018) Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 5(5):Cd001019. https://doi.org/10.1002/14651858.CD001019.pub3CrossRefPubMed

16.

Nowak RA (1999) Fibroids: pathophysiology and current medical treatment. Best Pract Res Clin Obstet Gynaecol 13(2):223–238CrossRef

17.

Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG et al (2021) Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr Rev 43(4):678–719. https://doi.org/10.1210/endrev/bnab039CrossRefPubMedCentral

18.

Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K (2012) Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health 12:1–11CrossRef

19.

Stovall DW (2001) Clinical symptomatology of uterine leiomyomas. Clin Obstet Gynecol 44(2):364–371. https://doi.org/10.1097/00003081-200106000-00022CrossRefPubMed

20.

Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R (2017) Epidemiology of uterine fibroids: a systematic review. BJOG: Int J Obstet Gynaecol 124(10):1501–12. https://doi.org/10.1111/1471-0528.14640CrossRef

21.

Reis FM, Bloise E, Ortiga-Carvalho TM (2016) Hormones and pathogenesis of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 34:13–24. https://doi.org/10.1016/j.bpobgyn.2015.11.015CrossRefPubMed

22.

Ishikawa H, Fenkci V, Marsh EE, Yin P, Chen D, Cheng YH et al (2008) CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma. J Clin Endocrinol Metab 93(3):981–991. https://doi.org/10.1210/jc.2007-2507CrossRefPubMedPubMedCentral

23.

Yonkers KA, O’Brien PMS, Eriksson E (2008) Premenstrual syndrome. Lancet 371(9619):1200–1210. https://doi.org/10.1016/S0140-6736(08)60527-9CrossRefPubMedPubMedCentral

24.

Halbreich U (2003) The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 28:55–99. https://doi.org/10.1016/S0306-4530(03)00097-0CrossRefPubMed

25.

Rapkin AJ, Akopians AL (2012) Pathophysiology of premenstrual syndrome and premenstrual dysphoric disorder. Menopause Int 18(2):52–59CrossRefPubMed

26.

Ford O, Lethaby A, Roberts H, Mol BW (2012) Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 3:Cd003415. https://doi.org/10.1002/14651858.CD003415.pub4CrossRef

27.

Grandi G, Barra F, Ferrero S, Sileo FG, Bertucci E, Napolitano A et al (2019) Hormonal contraception in women with endometriosis: a systematic review. Eur J Contracept Reprod Health Care 24(1):61–70. https://doi.org/10.1080/13625187.2018.1550576CrossRefPubMed

28.

Mitchell J-B, Chetty S, Kathrada F (2022) Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety. BMC Womens Health 22(1):526. https://doi.org/10.1186/s12905-022-02122-0CrossRefPubMedPubMedCentral

29.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. BMJ 2021:372

30.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898CrossRefPubMed

31.

Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S (2011) Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril 95(2):492–496. https://doi.org/10.1016/j.fertnstert.2010.08.042CrossRefPubMed

32.

Carr B, Dmowski WP, O’Brien C, Jiang P, Burke J, Jimenez R et al (2014) Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci 21(11):1341–1351. https://doi.org/10.1177/1933719114549848CrossRefPubMedPubMedCentral

33.

Caruso S, Cianci A, Iraci Sareri M, Panella M, Caruso G, Cianci S (2022) Randomized study on the effectiveness of nomegestrol acetate plus 17β-estradiol oral contraceptive versus dienogest oral pill in women with suspected endometriosis-associated chronic pelvic pain. BMC Womens Health 22(1):146. https://doi.org/10.1186/s12905-022-01737-7CrossRefPubMedPubMedCentral

34.

Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L (2018) Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil Steril 110(6):1129–1136. https://doi.org/10.1016/j.fertnstert.2018.07.003CrossRefPubMed

35.

Ceccaroni M, Clarizia R, Liverani S, Donati A, Ceccarello M, Manzone M et al (2021) Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial. Gynecol Endocrinol 37(10):930–933. https://doi.org/10.1080/09513590.2021.1929151CrossRefPubMed

36.

Cheewadhanaraks S, Choksuchat C, Dhanaworavibul K, Liabsuetrakul T (2012) Postoperative depot medroxyprogesterone acetate versus continuous oral contraceptive pills in the treatment of endometriosis-associated pain: a randomized comparative trial. Gynecol Obstet Invest 74(2):151–156. https://doi.org/10.1159/000337713CrossRefPubMed

37.

Crosignani PG, Luciano A, Ray A, Bergqvist A (2006) Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 21(1):248–256. https://doi.org/10.1093/humrep/dei290CrossRefPubMed

38.

El Taha L, Abu Musa A, Khalifeh D, Khalil A, Abbasi S, Nassif J (2021) Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 267:205–212. https://doi.org/10.1016/j.ejogrb.2021.10.029CrossRefPubMed

39.

Ferreira RA, Vieira CS, Rosa-E-Silva JC, Rosa-e-Silva AC, Nogueira AA, Ferriani RA (2010) Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception 81(2):117–122. https://doi.org/10.1016/j.contraception.2009.08.003CrossRefPubMed

40.

Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H et al (2009) Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis–a randomized, double-blind, multicenter, controlled trial. Fertil Steril 91(3):675–681. https://doi.org/10.1016/j.fertnstert.2007.12.080CrossRefPubMed

41.

Lang J, Yu Q, Zhang S, Li H, Gude K, von Ludwig C et al (2018) Dienogest for treatment of endometriosis in chinese women: a placebo-controlled, randomized, double-blind phase 3 study. J Womens Health (Larchmt) 27(2):148–155. https://doi.org/10.1089/jwh.2017.6399CrossRefPubMed

42.

Margatho D, Carvalho NM, Bahamondes L (2020) Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months. Eur J Contracept Reprod Health Care 25(2):133–140. https://doi.org/10.1080/13625187.2020.1725461CrossRefPubMed

43.

Razzi S, Luisi S, Ferretti C, Calonaci F, Gabbanini M, Mazzini M et al (2007) Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol 135(2):188–190. https://doi.org/10.1016/j.ejogrb.2006.08.002CrossRefPubMed

44.

Regidor PA, Regidor M, Schmidt M, Ruwe B, Lübben G, Förtig P et al (2001) Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol 15(3):202–209CrossRefPubMed

45.

Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A (2006) Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 85(2):314–325. https://doi.org/10.1016/j.fertnstert.2005.07.1315CrossRefPubMed

46.

Strowitzki T, Faustmann T, Gerlinger C, Seitz C (2010) Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 151(2):193–198. https://doi.org/10.1016/j.ejogrb.2010.04.002CrossRefPubMed

47.

Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Indhavivadhana S, Leerasiri P (2012) Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol 119(3):519–526. https://doi.org/10.1097/AOG.0b013e31824264c3CrossRefPubMed

48.

Tanmahasamut P, Saejong R, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Sanga-Areekul N (2017) Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecol Endocrinol 33(7):534–539. https://doi.org/10.1080/09513590.2017.1296124CrossRefPubMed

49.

Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG (2005) Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril 84(5):1375–1387. https://doi.org/10.1016/j.fertnstert.2005.03.083CrossRefPubMed

50.

Verspyck E, Marpeau L, Lucas C (2000) Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial. Eur J Obstet Gynecol Reprod Biol 89(1):7–13. https://doi.org/10.1016/s0301-2115(99)00168-2CrossRefPubMed

51.

Whitaker LHR, Middleton LJ, Daniels JP, Williams ARW, Priest L, Odedra S et al (2023) Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding (UCON): a randomised controlled phase III trial. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2023.101995CrossRefPubMedPubMedCentral

52.

Brown J, Kives S, Akhtar M (2012) Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002122.pub2CrossRefPubMedPubMedCentral

53.

Sangkomkamhang US, Lumbiganon P, Pattanittum P (2020) Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008994.pub3CrossRefPubMedPubMedCentral

54.

Curtis KM, Martins SL (2006) Progestogen-only contraception and bone mineral density: a systematic review. Contraception 73(5):470–487. https://doi.org/10.1016/j.contraception.2005.12.010CrossRefPubMed

55.

Jeng C-J, Chuang L, Shen J (2014) A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opin Pharmacother 15(6):767–773. https://doi.org/10.1517/14656566.2014.888414CrossRefPubMed

Title: The efficacy of progestins in managing pain associated with endometriosis, fibroids and pre-menstrual syndrome: a systematic review
Authors: Connor Luke Allen
Saikat Banerjee
Mahantesh Karoshi
Peter Humaidan
Farshad Tahmasebi
Publication date: 11-03-2025
Publisher: Springer Berlin Heidelberg
Keywords: Progestin
Endometriosis
Dienogest
Dysmenorrhoea
Leuprolide
Desogestrel
Flush
Lynestrenol
Published in: Archives of Gynecology and Obstetrics
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-025-07957-0

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now